Repligen Cp (RGEN) 31.04 $RGEN Repligen to Pres
Post# of 273258
Posted On: 09/02/2016 3:23:25 AM
Repligen Cp (RGEN) 31.04 $RGEN
Repligen to Present at Baird Global Healthcare Conference 2016
GlobeNewswire - Thu Sep 01, 6:30AM CDT
Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve the process of manufacturing biologic drugs, today announced that Tony J. Hunt, Chief Executive Officer, will present at Baird's annual Global Healthcare Conference being held September 7-8, 2016 in New York. The Repligen presentation will take place at 8:30 a.m. on Thursday, September 8th.
RGEN: 31.04 (+0.05)
Repligen Has Returned 19.8% Since SmarTrend Recommendation (RGEN)
Comtex SmarTrend(R) - Tue Aug 30, 1:20AM CDT
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on June 29th, 2016 at $25.99. In approximately 2 months, Repligen has returned 19.79% as of today's recent price of $31.14.
RGEN: 31.04 (+0.05)
Repligen Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 6:30AM CDT
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for the second quarter ended June 30, 2016. Detailed in this press release are the Company's performance highlights for the period, followed by updated financial guidance for the year 2016 and access information for today's webcast and conference call.
RGEN: 31.04 (+0.05)
Repligen to Present at Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 02, 6:30AM CDT
Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve the process of manufacturing biologic drugs, today announced that Tony J. Hunt, Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference at 8:00 a.m. ET on Wednesday, June 8 in New York.
RGEN: 31.04 (+0.05)
Repligen to Participate in 13th Annual Craig-Hallum Institutional Investor Conference
GlobeNewswire - Thu May 26, 1:52PM CDT
Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve the process of manufacturing biologic drugs, today announced that it will participate in the 13 Annual Craig-Hallum Institutional Investor Conference being held on June 1 in Minneapolis, MN. This conference provides institutional investors the opportunity to meet with Company management and does not include a formal presentation. Repligen's most recent investor presentation will be accessible through the Investor Events section of Company's website.
RGEN: 31.04 (+0.05)
Repligen Announces Pricing of $100 Million of 2.125% Convertible Senior Notes due 2021
GlobeNewswire - Thu May 19, 7:40AM CDT
Repligen Corporation (NASDAQ:RGEN) (the "Company"
today announced the pricing of an underwritten public offering of $100 million aggregate principal amount of 2.125% Convertible Senior Notes due 2021 (the "Notes" . The Company has granted the underwriters a 30-day option to purchase up to an additional $15 million aggregate principal amount of Notes. The offering is expected to close on or about May 24, 2016, subject to customary closing conditions. Jefferies is acting as the sole book-running manager, and Janney Montgomery Scott and Craig-Hallum Capital Group are acting as co-managers in the offering. Perella Weinberg Partners LP and J. Wood Capital Advisors LLC are serving as financial advisors to the Company in connection with the offering.
RGEN: 31.04 (+0.05)
Repligen Announces Proposed Public Offering of $100 Million of Convertible Senior Notes due 2021
GlobeNewswire - Wed May 18, 3:20PM CDT
Repligen Corporation (NASDAQ:RGEN) (the "Company" has commenced an offering of $100 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Notes" in an underwritten offering which includes the grant to the underwriter of a 30-day option to purchase up to an additional $15 million aggregate principal amount of Notes. Jefferies is the sole book-running manager for the offering.
RGEN: 31.04 (+0.05)
Repligen tops 1Q revenue forecasts
Automated Insights - Thu May 05, 2:37PM CDT
WALTHAM, Mass. (AP) _ Repligen Corp. (RGEN) on Thursday reported first-quarter profit of $1.6 million.
RGEN: 31.04 (+0.05)
Repligen to Report First Quarter 2016 Financial Results
GlobeNewswire - Fri Apr 29, 10:24AM CDT
Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report first quarter 2016 financial results on Thursday, May 5, 2016. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the reporting period ended March 31, 2016.
RGEN: 31.04 (+0.05)
The Biggest Threat to Repligen Stock
Keith Speights, The Motley Fool - Motley Fool - Fri Apr 29, 7:26AM CDT
Image source: Repligen. Last year demonstrated both the promise and the peril associated with investing in shares of Repligen Corporation . By late May, the bioprocessing leader's stock had doubled. By the end of 2015, most of those gains had...
RGEN: 31.04 (+0.05), GE: 31.20 (-0.04)
Repligen Acquires Atoll GmbH
GlobeNewswire - Mon Apr 04, 6:30AM CDT
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has acquired Atoll GmBH ("Atoll" of Weingarten, Germany, an innovator and manufacturer of MediaScout(R) pre-packed chromatography columns used in process development and clinical manufacturing of biologic drugs. The acquisition of Atoll expands Repligen's pre-packed column chromatography portfolio into high throughput process development screening, complementing the Company's existing strength in clinical production-scale columns. The combined offering will provide bioprocessing customers with breadth and flexibility in choosing column size, chromatography media and packed bed formats.
RGEN: 31.04 (+0.05)
Repligen Forms Scientific Advisory Board
GlobeNewswire - Thu Mar 31, 7:46AM CDT
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced its formation of a Scientific Advisory Board ("SAB" to provide thought leadership and oversight of the Company's innovation initiatives. The SAB will focus on expansion of Repligen's bioprocessing product portfolio as well as identification and evaluation of new strategic opportunities. It is comprised of some of the world's most recognized experts and trailblazers in the field of biopharmaceutical manufacturing.
RGEN: 31.04 (+0.05)
Downtrend Call Working As Repligen Stock Falls 17.0% (RGEN)
Comtex SmarTrend(R) - Fri Feb 05, 6:51PM CST
SmarTrend identified a Downtrend for Repligen (NASDAQ:RGEN) on November 6th, 2015 at $26.28. In approximately 3 months, Repligen has returned 16.99% as of today's recent price of $21.81.
RGEN: 31.04 (+0.05)
18.0% Return Seen to Date on SmarTrend Repligen Call (RGEN)
Comtex SmarTrend(R) - Fri Jan 29, 10:43AM CST
SmarTrend identified a Downtrend for Repligen (NASDAQ:RGEN) on November 6th, 2015 at $26.28. In approximately 3 months, Repligen has returned 17.96% as of today's recent price of $21.56.
RGEN: 31.04 (+0.05)
Why You Shouldn't Bet Against Repligen (RGEN) Stock
Zacks Equity Research - Zacks Investment Research - Tue Dec 29, 8:03AM CST
Repligen is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
RGEN: 31.04 (+0.05)
Repligen to Present at the Stifel 2015 Healthcare Conference
GlobeNewswire - Wed Nov 11, 6:30AM CST
Repligen Corporation (NASDAQ:RGEN) today announced its upcoming presentation at the Stifel 2015 Healthcare Conference, being held next week at the Lotte New York Palace. Tony J. Hunt, Repligen President and Chief Executive Officer, will present a Company overview on Wednesday, November 18, at 8:00 a.m. EST. A live audio webcast of this discussion will be accessible through the Investor Events section of Company's website. A replay of the webcast will also be accessible for a period of time following the event.
RGEN: 31.04 (+0.05)
Chromatography Resin Market by Type, by Technique and by Application - Global Forecasts to 2020 - Market to be Worth 2.3 Billion USD
M2 - Wed Nov 11, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/kp2zz9/chromatography) has announced the addition of the "Chromatography Resin Market by Type, by Technique and by Application - Global Forecasts to 2020" report to their offering. The market for chromatography resins is estimated to have accounted for USD 1.5 billion in 2014 and is projected to register a CAGR of 7.3% between 2015 and 2020, and reach the market size USD 2.3 billion by 2020 Chromatography resins are polymers used as media in chromatographic techniques, namely, ion exchange, affinity, hydrophobic interaction, size exclusion, multi-modal and others (partition and adsorption). This report on chromatography resins market covers all major regions such as Asia-Pacific, Europe, North America, and Rest of the World. The report includes analysis of market trends and forecasts from 2013 to 2020. Market estimations have been provided in terms of consumption volume (Liter) and value (USD). The report includes analyzsis of the market dynamics such as drivers, restraints, and opportunities, and winning imperatives. Major companies such as Merck KGaA, General Electric Company, Thermo Fisher Scientific Inc., Tosoh Corporation, Bio-Rad Laboratories, Inc., Repligen Corporation, Purolite Corporation, Avantor Performance Materials, Inc., Mitsubishi Chemical Corporation, and Pall Corporation. The chromatography resins market which is highly consolidated with presence of large number of global manufacturers. The key players of the market are well established and have a strong foothold in the market. The market is highly competitive in nature. The report also includes the analysis of competitive landscape based on the recent developments in the market. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Chromatography Resin Market, By Type 7 Chromatography Resin Market, By Technique 8 Chromatography Resin Market, By Application 9 Chromatography Resin Market, Regional Analysis 10 Competitive Landscape 11 Company Profiles 12 Appendix Companies Mentioned - Avantor Performance Materials, Inc. - Bio-Rad Laboratories, Inc. - General Electric Company (GE Healthcare) - Merck KGAA - Mitsubishi Chemical Corporation - Pall Corporation - Purolite Corporation - Repligen Corporation - Thermo Fisher Scientific Inc. - Tosoh Corporation For more information visit http://www.researchandmarkets.com/research/kp...matography
RGEN: 31.04 (+0.05), GE: 31.20 (-0.04), PLL: 127.11 (-0.01)
Chromatography Resin Market by Type, by Technique, by Application - Global Forecasts to 2020
M2 - Mon Nov 09, 1:46AM CST
The market for chromatography resins is estimated to have accounted for USD 1.5 billion in 2014 and is projected to register a CAGR of 7.3% between 2015 and 2020, and reach the market size USD 2.3 billion by 2020. Chromatography resins are polymers used as media in chromatographic techniques, namely, ion exchange, affinity, hydrophobic interaction, size exclusion, multi-modal and others (partition and adsorption). This report on chromatography resins market covers all major regions such as Asia-Pacific, Europe, North America, and Rest of the World. The report includes analysis of market trends and forecasts from 2013 to 2020. Market estimations have been provided in terms of consumption volume (Liter) and value (USD).
RGEN: 31.04 (+0.05), GE: 31.20 (-0.04)
Why Repligen Corporation Shares Are Falling
Todd Campbell, The Motley Fool - Motley Fool - Fri Nov 06, 12:49PM CST
Source: Repligen What: After reporting third quarter financial results, updating investors on its outlook, and receiving a Wall Street downgrade, shares in Repligen Corporation tumbled by nearly 20% today. So what: In the third quarter,...
RGEN: 31.04 (+0.05)
Repligen to Present at Baird Global Healthcare Conference 2016
GlobeNewswire - Thu Sep 01, 6:30AM CDT
Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve the process of manufacturing biologic drugs, today announced that Tony J. Hunt, Chief Executive Officer, will present at Baird's annual Global Healthcare Conference being held September 7-8, 2016 in New York. The Repligen presentation will take place at 8:30 a.m. on Thursday, September 8th.
RGEN: 31.04 (+0.05)
Repligen Has Returned 19.8% Since SmarTrend Recommendation (RGEN)
Comtex SmarTrend(R) - Tue Aug 30, 1:20AM CDT
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on June 29th, 2016 at $25.99. In approximately 2 months, Repligen has returned 19.79% as of today's recent price of $31.14.
RGEN: 31.04 (+0.05)
Repligen Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 6:30AM CDT
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for the second quarter ended June 30, 2016. Detailed in this press release are the Company's performance highlights for the period, followed by updated financial guidance for the year 2016 and access information for today's webcast and conference call.
RGEN: 31.04 (+0.05)
Repligen to Present at Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 02, 6:30AM CDT
Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve the process of manufacturing biologic drugs, today announced that Tony J. Hunt, Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference at 8:00 a.m. ET on Wednesday, June 8 in New York.
RGEN: 31.04 (+0.05)
Repligen to Participate in 13th Annual Craig-Hallum Institutional Investor Conference
GlobeNewswire - Thu May 26, 1:52PM CDT
Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve the process of manufacturing biologic drugs, today announced that it will participate in the 13 Annual Craig-Hallum Institutional Investor Conference being held on June 1 in Minneapolis, MN. This conference provides institutional investors the opportunity to meet with Company management and does not include a formal presentation. Repligen's most recent investor presentation will be accessible through the Investor Events section of Company's website.
RGEN: 31.04 (+0.05)
Repligen Announces Pricing of $100 Million of 2.125% Convertible Senior Notes due 2021
GlobeNewswire - Thu May 19, 7:40AM CDT
Repligen Corporation (NASDAQ:RGEN) (the "Company"
today announced the pricing of an underwritten public offering of $100 million aggregate principal amount of 2.125% Convertible Senior Notes due 2021 (the "Notes" . The Company has granted the underwriters a 30-day option to purchase up to an additional $15 million aggregate principal amount of Notes. The offering is expected to close on or about May 24, 2016, subject to customary closing conditions. Jefferies is acting as the sole book-running manager, and Janney Montgomery Scott and Craig-Hallum Capital Group are acting as co-managers in the offering. Perella Weinberg Partners LP and J. Wood Capital Advisors LLC are serving as financial advisors to the Company in connection with the offering. RGEN: 31.04 (+0.05)
Repligen Announces Proposed Public Offering of $100 Million of Convertible Senior Notes due 2021
GlobeNewswire - Wed May 18, 3:20PM CDT
Repligen Corporation (NASDAQ:RGEN) (the "Company"
has commenced an offering of $100 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Notes" in an underwritten offering which includes the grant to the underwriter of a 30-day option to purchase up to an additional $15 million aggregate principal amount of Notes. Jefferies is the sole book-running manager for the offering. RGEN: 31.04 (+0.05)
Repligen tops 1Q revenue forecasts
Automated Insights - Thu May 05, 2:37PM CDT
WALTHAM, Mass. (AP) _ Repligen Corp. (RGEN) on Thursday reported first-quarter profit of $1.6 million.
RGEN: 31.04 (+0.05)
Repligen to Report First Quarter 2016 Financial Results
GlobeNewswire - Fri Apr 29, 10:24AM CDT
Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report first quarter 2016 financial results on Thursday, May 5, 2016. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the reporting period ended March 31, 2016.
RGEN: 31.04 (+0.05)
The Biggest Threat to Repligen Stock
Keith Speights, The Motley Fool - Motley Fool - Fri Apr 29, 7:26AM CDT
Image source: Repligen. Last year demonstrated both the promise and the peril associated with investing in shares of Repligen Corporation . By late May, the bioprocessing leader's stock had doubled. By the end of 2015, most of those gains had...
RGEN: 31.04 (+0.05), GE: 31.20 (-0.04)
Repligen Acquires Atoll GmbH
GlobeNewswire - Mon Apr 04, 6:30AM CDT
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has acquired Atoll GmBH ("Atoll"
of Weingarten, Germany, an innovator and manufacturer of MediaScout(R) pre-packed chromatography columns used in process development and clinical manufacturing of biologic drugs. The acquisition of Atoll expands Repligen's pre-packed column chromatography portfolio into high throughput process development screening, complementing the Company's existing strength in clinical production-scale columns. The combined offering will provide bioprocessing customers with breadth and flexibility in choosing column size, chromatography media and packed bed formats. RGEN: 31.04 (+0.05)
Repligen Forms Scientific Advisory Board
GlobeNewswire - Thu Mar 31, 7:46AM CDT
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced its formation of a Scientific Advisory Board ("SAB"
to provide thought leadership and oversight of the Company's innovation initiatives. The SAB will focus on expansion of Repligen's bioprocessing product portfolio as well as identification and evaluation of new strategic opportunities. It is comprised of some of the world's most recognized experts and trailblazers in the field of biopharmaceutical manufacturing. RGEN: 31.04 (+0.05)
Downtrend Call Working As Repligen Stock Falls 17.0% (RGEN)
Comtex SmarTrend(R) - Fri Feb 05, 6:51PM CST
SmarTrend identified a Downtrend for Repligen (NASDAQ:RGEN) on November 6th, 2015 at $26.28. In approximately 3 months, Repligen has returned 16.99% as of today's recent price of $21.81.
RGEN: 31.04 (+0.05)
18.0% Return Seen to Date on SmarTrend Repligen Call (RGEN)
Comtex SmarTrend(R) - Fri Jan 29, 10:43AM CST
SmarTrend identified a Downtrend for Repligen (NASDAQ:RGEN) on November 6th, 2015 at $26.28. In approximately 3 months, Repligen has returned 17.96% as of today's recent price of $21.56.
RGEN: 31.04 (+0.05)
Why You Shouldn't Bet Against Repligen (RGEN) Stock
Zacks Equity Research - Zacks Investment Research - Tue Dec 29, 8:03AM CST
Repligen is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
RGEN: 31.04 (+0.05)
Repligen to Present at the Stifel 2015 Healthcare Conference
GlobeNewswire - Wed Nov 11, 6:30AM CST
Repligen Corporation (NASDAQ:RGEN) today announced its upcoming presentation at the Stifel 2015 Healthcare Conference, being held next week at the Lotte New York Palace. Tony J. Hunt, Repligen President and Chief Executive Officer, will present a Company overview on Wednesday, November 18, at 8:00 a.m. EST. A live audio webcast of this discussion will be accessible through the Investor Events section of Company's website. A replay of the webcast will also be accessible for a period of time following the event.
RGEN: 31.04 (+0.05)
Chromatography Resin Market by Type, by Technique and by Application - Global Forecasts to 2020 - Market to be Worth 2.3 Billion USD
M2 - Wed Nov 11, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/kp2zz9/chromatography) has announced the addition of the "Chromatography Resin Market by Type, by Technique and by Application - Global Forecasts to 2020" report to their offering. The market for chromatography resins is estimated to have accounted for USD 1.5 billion in 2014 and is projected to register a CAGR of 7.3% between 2015 and 2020, and reach the market size USD 2.3 billion by 2020 Chromatography resins are polymers used as media in chromatographic techniques, namely, ion exchange, affinity, hydrophobic interaction, size exclusion, multi-modal and others (partition and adsorption). This report on chromatography resins market covers all major regions such as Asia-Pacific, Europe, North America, and Rest of the World. The report includes analysis of market trends and forecasts from 2013 to 2020. Market estimations have been provided in terms of consumption volume (Liter) and value (USD). The report includes analyzsis of the market dynamics such as drivers, restraints, and opportunities, and winning imperatives. Major companies such as Merck KGaA, General Electric Company, Thermo Fisher Scientific Inc., Tosoh Corporation, Bio-Rad Laboratories, Inc., Repligen Corporation, Purolite Corporation, Avantor Performance Materials, Inc., Mitsubishi Chemical Corporation, and Pall Corporation. The chromatography resins market which is highly consolidated with presence of large number of global manufacturers. The key players of the market are well established and have a strong foothold in the market. The market is highly competitive in nature. The report also includes the analysis of competitive landscape based on the recent developments in the market. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Chromatography Resin Market, By Type 7 Chromatography Resin Market, By Technique 8 Chromatography Resin Market, By Application 9 Chromatography Resin Market, Regional Analysis 10 Competitive Landscape 11 Company Profiles 12 Appendix Companies Mentioned - Avantor Performance Materials, Inc. - Bio-Rad Laboratories, Inc. - General Electric Company (GE Healthcare) - Merck KGAA - Mitsubishi Chemical Corporation - Pall Corporation - Purolite Corporation - Repligen Corporation - Thermo Fisher Scientific Inc. - Tosoh Corporation For more information visit http://www.researchandmarkets.com/research/kp...matography
RGEN: 31.04 (+0.05), GE: 31.20 (-0.04), PLL: 127.11 (-0.01)
Chromatography Resin Market by Type, by Technique, by Application - Global Forecasts to 2020
M2 - Mon Nov 09, 1:46AM CST
The market for chromatography resins is estimated to have accounted for USD 1.5 billion in 2014 and is projected to register a CAGR of 7.3% between 2015 and 2020, and reach the market size USD 2.3 billion by 2020. Chromatography resins are polymers used as media in chromatographic techniques, namely, ion exchange, affinity, hydrophobic interaction, size exclusion, multi-modal and others (partition and adsorption). This report on chromatography resins market covers all major regions such as Asia-Pacific, Europe, North America, and Rest of the World. The report includes analysis of market trends and forecasts from 2013 to 2020. Market estimations have been provided in terms of consumption volume (Liter) and value (USD).
RGEN: 31.04 (+0.05), GE: 31.20 (-0.04)
Why Repligen Corporation Shares Are Falling
Todd Campbell, The Motley Fool - Motley Fool - Fri Nov 06, 12:49PM CST
Source: Repligen What: After reporting third quarter financial results, updating investors on its outlook, and receiving a Wall Street downgrade, shares in Repligen Corporation tumbled by nearly 20% today. So what: In the third quarter,...
RGEN: 31.04 (+0.05)
(0)
(0)Scroll down for more posts ▼